Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TG-HEX is a combination pharmaceutical product developed by Novogen Captab, containing terbutaline, ambroxol, guaifenesin, and menthol. It is typically indicated for the treatment of cough associated with respiratory conditions such as bronchitis, bronchial asthma, and emphysema. Terbutaline acts as a bronchodilator by stimulating beta-2 adrenergic receptors, leading to relaxation of bronchial smooth muscle. Ambroxol is a mucolytic agent that thins and loosens mucus, while guaifenesin is an expectorant that promotes the clearance of mucus from the airways by increasing the volume and reducing the viscosity of secretions. Menthol provides a cooling sensation and helps relieve minor throat irritation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TG-HEX.